Insights
Subject access requests: key issues for the pharmaceuticals and life sciences sector
05 Jan 2026Subject access requests (SARs) continue to pose significant challenges for organisations in the pharmaceuticals and life sciences sector. They are often time-consuming, resource-intensive and frequently linked to wider complaints or disputes. This article shares some practical tips to help organisations manage SARs effectively.
AI and Copyright: Updates from the Data (Use and Access) Act 2025 progress statement
05 Jan 2026The DUAA progress statement provides useful insights on regulation of AI, so that businesses can proactively address risk.
US-UK tariff deal and reimbursement increase a gamechanger for UK pharma
05 Jan 2026After much uncertainty and concern, finally some incredibly positive news for the UK life sciences sector.
New Year's regulations - What does your business need to know for 2026?
27 Nov 2025Now that the start of the festive period approaches, many of us are making personal New Year's resolutions and goals for the next year. This is also a great time to pause and consider the upcoming regulatory changes for the sector, and the steps your business can take to be in the best position for 2026.
London showcases life sciences leadership after buzzing London Life Sciences Week
27 Nov 2025Over 100 events. More than 1,500 different people attending. Patrick Vallance, Zubir Ahmed, Sadiq Khan, Sam Barrell, Steve Bates and many more.
Your business is considering decentralised manufacturing for a product - what are the steps you need to take?
06 Nov 2025As discussed in our previous article, the UK is the first country to have implemented a framework to allow Point of Care (POC) and Modular Manufacturing (MM), together known as Decentralised Manufacturing (DM). This is a really exciting step, particularly for the area of personalised medicines, but there are certain considerations and mandatory steps for businesses to take before they implement DM processes.
